Dr. Neil Iyengar highlighted lifestyle interventions as part of cancer care, citing evidence that exercise improves quality of life, treatment adherence, survival, and may favorably alter the tumor microenvironment.

Dr. Anna Garrido-Castro reviewed ADC sequencing in HER2-negative breast cancer, highlighting T-DXd and SG, resistance mechanisms, and emerging bispecific ADCs to improve outcomes after prior ADC therapy.

Dr. Antonio Giordano reviewed next-generation ADCs targeting HER3, EGFR, and nectin-4. Early trials showed promising activity, with future strategies focused on novel targets, payloads, and combination therapies.

Dr. Claudine Isaacs reviewed HER2-targeted ADCs, highlighting T-DXd’s superiority over standard therapy in improving pCR and invasive disease-free survival. Ongoing work focuses on optimal sequencing and biomarker-guided use.

Panelists recommended THP for most early HER2-positive breast cancers, reserving T-DXd for higher-risk disease. They emphasized biomarker-guided ADC sequencing and improved clinical trial design.